Retraction Note to: Mol Biol Rep (2014) 41(2):1165–1170 DOI 10.1007/s11033-013-2963-y

The Editor-in-Chief of Molecular Biology Reports retracts the above-mentioned article per the Committee on Publication Ethics guidelines on plagiarism and related questionable writing practices. The article uses as a template substantial portions of text of which a large part have been paraphrased in order to describe another association of FGFR4 polymorphisms with a disease (NHL versus CAD) from the following source(s):

Lan Ma, Haifeng Zhang, Carrie Han, Danian Tong, Meiyan Zhang, Yi'an Yao, Yu Luo, and Xuebo Liu, Fibroblast growth factor receptor 4 polymorphisms and susceptibility to coronary artery disease, DNA and Cell Biology. June 2012, 31(6): 1064–1069. doi:10.1089/dna.2011.1552.

Qing Zhu, Tongtao Liu, Fibroblast growth factor receptor 4 polymorphisms and coronary artery disease: a case control study, Molecular Biology Reports, June 2012, 39(9): 8679–8685. doi:10.1007/s11033-012-1723-8.

HF Zhang, KJ Zhao, PF Yang, YB Fang, YH Zhang, JM Liu and QH Huang, Association between fibroblast growth factor receptor 4 Gly388Arg polymorphism and ischaemic stroke, The Journal of International Medical Research, October 2012, 40(5): 1708–1714. doi:10.1177/030006051204000509.

Chen H, Tong J, Zou T, Shi H, Liu J, Du X, Yang J, Ma C, Fibroblast growth factor receptor 4 polymorphisms are associated with coronary artery disease. Genet Test Mol Biomarkers, 16:952–956, 2012.

In addition, further investigation showed irregularities in the peer review process leading us to believe that the peer review process was compromised.